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Abstract 
A major risk factor for the development of Alzheimer’s disease is increasing age 
but the reason behind this association has not been identified. It is thought that 
the changes in endocytosis seen in Alzheimer’s disease patients are causal for 
this condition. Thus we hypothesised that the increased risk of developing 
Alzheimer’s disease associated with ageing may be due to changes in 
endocytosis. We investigated using Western blotting whether the expression of 
endocytic proteins involved in clathrin-mediated and clathrin-independent 
endocytosis are altered by increasing age in a mouse model of amyloid 
pathology. We used mice transgenic for human amyloid precursor protein 
containing the V717I London mutation. We compared London mutation mice 
with age-matched wild-type controls at three ages, 3, 9 and 18 months, 
representing different stages in the development of pathology in this model. 
Having verified that the London mutation mice over-expressed amyloid 
precursor protein and β-amyloid, we found that the expression of the smallest 
isoform of PICALM, a key protein involved in the regulation of clathrin-coated pit 
formation, was significantly increased in wild-type mice but decreased in 
London mutation mice with age. PICALM levels in wild-type 18-month mice and 
clathrin levels in wild-type 9-month mice were significantly higher than those in 
London mutation mice of the same ages. The expression of caveolin-1, involved 
in clathrin-independent endocytosis, was significantly increased with age in all 
mice. Our results suggest that endocytic processes could be altered by the 
ageing process and such changes could partly explain the association between 
ageing and Alzheimer’s disease. 
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Introduction 
Dementia currently affects about 47.5 million people worldwide [1] with 
Alzheimer’s disease (AD) being the most common cause [1,2]. The major risk 
factor for developing AD is increasing age, with about 11% of people aged 65 
and over having the disease, rising to 32% over the age of 85 [2]. It is estimated 
that by 2050 there will be over 115 million people in the world with AD [3]. 
However, few studies have considered how ageing may contribute to the 
aetiology of the disease.  
 
Alterations in endocytosis represent a potential mechanism which could 
underlie the association of AD with age. Changes in endocytosis were first 
identified in cases of AD twenty years ago [4]. Since 2009, a number of 
Genome Wide Association Studies have described polymorphisms in genes 
associated with a small increased risk of developing AD and at least three of the 
proteins encoded by these genes, PICALM, BIN1 and SORL1, are involved in 
endocytosis [5], emphasising the importance of this pathway in AD. Amyloid 
precursor protein (APP), the source of –amyloid (A), a key protein involved in 
the pathology of AD, is transported via the secretory pathway to the cell surface 
and is then internalised by endocytosis. Most amyloidogenic processing occurs 
only after this event, within the endocytic/lysosomal system [6,7]. Endocytosis is 
thus central to the production of Aβ. 
 
Clathrin-mediated endocytosis (CME) involves many different proteins including 
the scission protein dynamin and regulatory accessory or adaptor proteins such 
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as AP180, PICALM, amphiphysin I and BIN1 [8]. Changes in CME have been 
seen in AD and associated models of amyloid pathology. Early endocytic 
changes, as evidenced by an increase in the number and size of Rab5-positive 
endosomes, are present in Down Syndrome and AD brains [9]. Importantly, 
inhibition of both CME in vivo in APP transgenic mice and dynamin-dependent 
endocytosis in vitro lowered Aβ levels [10,11], while up-regulation of 
endocytosis increased APP metabolism to sAPPβ and βCTF and increased Aβ 
secretion [7].  
 
Lipid rafts in the plasma membrane are also important for modulating Aβ 
production [12,13]. Caveolae are a type of lipid raft enriched with caveolins-1-3 
and are associated with processes including clathrin-independent endocytosis 
(CIE) [14]. Flotillin-1 and -2, also found in lipid rafts, non-caveolar lipid raft 
microdomains in neurones that may also be implicated in endocytosis [15,16]. 
Alterations in caveolins have been associated with AD as the expression of 
caveolin-1 is elevated in the hippocampus in AD compared to non-AD brains 
[17]. 
 
We have previously considered the importance of changes in endocytosis with 
ageing for AD pathophysiology by examining the expression of several CME 
and CIE-related endocytic proteins in the cortex of aged transgenic (Tg) Tg2576 
mice expressing the Swedish mutation of human APP at the β-secretase 
cleavage site [18]. Using 22 month-old male mice, we found significantly higher 
levels of clathrin heavy chain (CHC), dynamin II and PICALM compared to wild-
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type (WT) mice but no changes in proteins involved in CIE [18]. However, we 
did not compare different ages. Therefore we have now investigated how 
ageing and the presence of amyloid pathology affect the expression of a range 
of proteins involved in CME and CIE. We have used the London V717I mouse, 
a well-characterised model of amyloid pathology that overexpresses human 
APP695 with a mutation at V717I [19]. In contrast to our earlier data from the 
Tg2576 mouse [18], we did not see any changes in clathrin expression with age 
or between genotypes but we did identify an increase in the expression of 
caveolin-1 with age in WT and Tg mice. Furthermore, interestingly we saw an 
increase in the expression of an isoform of PICALM in WT mice but a decrease 
in Tg mice with age.  
 
Methods 
Materials 
All chemicals and reagents were purchased from Sigma-Aldrich, Poole, U.K. or 
Fisher Scientific, Leicester, U.K unless specified. Antibodies used in Western 
blotting were: anti N-APP, 22C11 (Millipore, Watford, U.K.); anti-clathrin heavy 
chain (CHC, Clone 23), anti-caveolin-1, anti-caveolin-2 (Clone 65), anti-flotillin-1 
(Clone 18), (BD Biosciences, Oxford, UK); anti-GAPDH (Sigma-Aldrich); anti-
BIN1 (Santa Cruz, Wembley, U.K.); anti-PICALM, anti-flotillin-2 (Novus 
Biologicals, Littleton, CO, USA); anti-dynamin-1 (Abcam, Cambridge, MA). 
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Mice 
Tg mice carrying the London V717I mutation in human APP [19] were 
maintained on the in-bred C57Bl/6 background. All work described here 
complied with the guidelines for the care and use of laboratory animals 
according to the Animals (Scientific Procedures) Act 1986 and in accordance 
with Home Office (U.K.) regulations and European Union directive 2010/63/EU. 
 
Protein Extraction 
Soluble and insoluble proteins were extracted from the total cortices of male 3, 
9 and 18-month old London Tg mice and WT aged-matched littermates 
following the method of Rees et al. [18,20]. Total protein concentration was 
determined with the BCA Protein Assay Kit (Thermo Scientific, Waltham, USA). 
 
Western Blotting 
Western Blotting was performed using standard methods. Briefly, after protein 
analysis, 10µg of all samples were resolved on 10% polyacrylamide gels, and 
detected with the relevant antibody as previously described [18]. 
 
ELISA 
Soluble and insoluble human Aβ40 and 42 were detected by ELISA as 
previously described [18]. 
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Statistical analyses 
The Western blot shown for each protein was quantified using Image J 
(www.imagej.nih.gov). All protein bands were expressed as the relative density 
of WT cortex sample 1 and then normalised for relative GAPDH levels. ELISA 
data were expressed as ng Aβ/mg total protein. The blotting data were analysed 
by one-way ANOVA followed by Tukey’s post-hoc tests or by unpaired 
Student’s t-tests to determine if protein levels differed significantly between 
ages or between Tg and age-matched WT mice, respectively. ELISA data were 
analysed using Kruskal-Wallis followed by Dunn’s multiple comparisons test 
(soluble Aβ) or one-way ANOVA followed by Fisher’s LSD test (insoluble Aβ40). 
Where necessary, data were transformed to fit the assumptions of normality. 
 
Results 
Expression of APP, Aβ40 and Aβ42 in the Tg and WT mice 
As expected the expression of APP was significantly increased by about 3-fold 
in the cortex of 18-month Tg mice compared to WT mice (p<0.05) (Fig. 1A). The 
levels of APP were not altered by ageing in either WT or Tg mice (see Figure 
Supplemental Digital Content 1). Soluble and insoluble Aβ40 and soluble Aβ42 
levels from the overexpressed human APP were all significantly increased in 
18-month Tg mice compared to younger mice (p<0.05) (Fig. 2A, B).  
 
Levels of proteins involved in CME are altered by ageing and APP genotype  
No significant differences in the levels of clathrin heavy chain (CHC) with 
increasing age were detected in either WT or Tg mice (Fig. 1B,C). In contrast, 
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when the level of clathrin was compared between WT and Tg mice brains, a 
significant decrease was seen in 9-month Tg mice, 0.3 ± 0.02 compared to 0.8 
± 0.1 in WT mice (p < 0.001, OD ratio relative to GAPDH). There were no 
significant changes in the levels of clathrin between WT and Tg mice aged 3 
and 18 months (see Table Supplemental Digital Content 2).  
The levels of dynamin I were not significantly altered by ageing in either WT or 
Tg mice (see Figure Supplemental Digital Content 1). Furthermore, no changes 
in dynamin were observed between WT and Tg mice of the same age (see 
Table Supplemental Digital Content 2).  
At least 6 isoforms of Mus musculus PICALM have been found with predicted 
molecular masses ranging from approximately 64 to 72 kDa (NCBI RefSeq). We 
identified PICALM as 3 distinct bands at 72, 68, and 62 kDa (Fig. 1D-F). The 
largest bands (bands 1 and 2) were analysed together as they were not fully 
resolved. There was no detectable change in the levels of bands 1 and 2 with 
ageing in either WT or Tg mice (Fig. 1E,F). There were also no changes in the 
expression of bands 1 and 2 between WT and Tg mice aged 3, 9 and 18 
months (Fig. 1D, see Table Supplemental Digital Content 2). However, 
expression of the smallest band of PICALM (band 3) was significantly increased 
in 18-month WT mice compared to 9-month mice (Fig. 1E) but  was significantly 
decreased in 18-month Tg mice compared to 3-month mice (Fig. 1F). 
Furthermore, the levels of band 3 were significantly reduced by approximately 6 
times in 18-month Tg mice when compared to WT mice (Fig. 1D). In contrast, 
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there were no changes in the expression of band 3 between WT and Tg mice 
aged 3 and 9 months (see Table Supplemental Digital Content 2). 
At least 15 different isoforms of bridging integrator 1 (Bin-1) have been 
identified. Here, two bands were observed for Bin-1 (see Figure Supplemental 
Digital Content 1). The levels of Bin-1 were not significantly altered in Tg mice 
compared to WT mice at any age point (see Table Supplemental Digital Content 
2). Similarly, no significant changes were detected in the levels of Bin-1 with 
ageing in either WT or Tg mice (see Figure Supplemental Digital Content 1).  
 
Levels of proteins involved in CIE are altered by ageing and genotype  
The levels of caveolin-1 were significantly higher in both 9- and -18 month WT 
and Tg mice compared to 3-month mice (Fig. 2A,B). However, the levels of 
caveolin-1 were not altered between 3- and 9-month old WT and Tg mice (see 
Table Supplemental Digital Content 2) but were significantly decreased by 
approximately 1.4 times in 18-month Tg compared to WT mice (Fig. 2C). 
Caveolin-2 expression in WT and Tg mice was not altered by age or genotype 
(see Figure and Table Supplemental Digital Content 1 and 2). Neither flotillin-1 
nor flotillin-2 in WT and Tg mice were affected by age or genotype (see Figure 
and Table Supplemental Digital Content 1 and 2).  
 
Discussion 
The results presented here show that both ageing and genotype affected the 
expression of endocytic proteins in the cortex of WT and Tg V717I London 
 13 
 
mutation mice. The data obtained for APP expression confirmed firstly that the 
Tg London mutation mice over-expressed APP compared to the WT mice and 
secondly showed no change in APP expression with age, as expected from 
other studies [21]. This overexpression of APP led to the expected increase in 
human Aβ40 and 42 in the 18-month Tg mice. 
 
Interestingly, although there is much evidence, reviewed above, to show that 
CME is affected in AD and implicated in the pathogenesis of the disease, we 
saw limited changes in clathrin itself with a decrease only in 9-month Tg mice 
compared to WT mice. We know that cognitive deficits start to appear around 6-
9 months of age in these mice which could be linked to the change in clathrin 
seen here (unpublished data). Interestingly, the decrease in clathrin precedes 
the increase in Aβ in these mice so a small change in endocytosis in earlier life 
might be linked to the subsequent rise in Aβ levels in these mice. However, in 
the cortex of the London mutation mice neither age nor the presence of amyloid 
pathology appeared to have a large effect on CME as determined by the 
expression levels of clathrin. Support is provided for this conclusion by the data 
for dynamin-1, PICALM bands 1 and 2 and Bin-1 where no changes in 
expression were seen. This is particularly significant for dynamin-1, crucial for 
CME to occur but also for many forms of CIE. The data for band 3 for PICALM, 
however, do not fit with this conclusion as its expression was differentially 
affected by both age and genotype. Currently, the function of the different 
PICALM isoforms is not understood and we have previously shown that at least 
human isoforms 1 and 2 are required for PICALM to affect functional 
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endocytosis in the H4 cell line [22]. The most likely explanation for these 
findings lies in another role of PICALM, in addition to its involvement in CME. 
More specifically, PICALM controls the endocytosis of R-SNAREs (Soluble NSF 
Attachment Protein Receptors) necessary for the fusion of endocytic vesicles 
with endosomes or the plasma membrane [23].  
 
There does appear to be some involvement of ageing and genotype in CIE as 
the expression of caveolin-1 was increased in both genotypes with age but to a 
larger extent in the WT mice. Furthermore, this increase in caveolin-1 preceded 
the increase in Aβ40 and 42 in the Tg mice supporting the data with clathrin and 
possibly suggesting that changes in endocytosis could be linked to subsequent 
increases in Aβ accumulation. Another study also found an increase in caveolin-
1 with age in WT mice [17]. This is an interesting result as loss of caveolin-1 is 
associated with accelerated aging and neurodegeneration in mice [24]. These 
data support those for caveolin-1 expression in the human brain where higher 
expression was seen in the hippocampus from AD brains compared to non-AD 
brains [17]. We also detected a significant rise in caveolin-1 expression in 
human AD frontal cortex compared to age-matched controls (unpublished data). 
Another study found no changes in caveolin-1 in human cortex comparing AD 
and control individuals [25] but the effect of age was not considered. The other 
CIE proteins examined here, caveolin-2, flotillin-1 and -2 were not affected by 
ageing or genotype suggesting that any effect of these factors on CIE in mice is 
not wide-spread.  
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The results we have obtained here for various endocytic proteins in the V717I 
London mutation mice contrast with those we obtained for the same proteins in 
old Tg2576 mice [18]. One possible explanation for these differences lies in the 
different mutations affecting the -secretase (Tg2575) and -secretase (V717I) 
cleavage sites in APP leading to higher levels of APP and 10 to over 1400-fold 
increases in A in the Tg2576 mice [18]. In addition, the different genetic 
backgrounds of the two mice strains probably also affect other proteins and 
biochemical pathways such as those involved in endocytosis.  
 
In conclusion, we have shown that proteins involved in both CME and CIE are 
affected by ageing and also by the presence of amyloid pathology in mice. Our 
data provide support for the idea that changes in endocytosis are involved in the 
pathogenesis of AD. 
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Figure 1 
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Figure 1. Comparison of APP, clathrin heavy chain, and 3 bands for PICALM in 
the cortex of male WT and Tg mice aged 3, 9 and 18 months. Each section 
shows an immunoblot and densitometric analysis of the immunoblot. (A) 
Comparison of APP expression in 18 month WT and Tg mice; comparison of 
clathrin expression in (B) WT mice and (C) Tg mice aged 3, 9 and 18 months; 
comparison of PICALM bands 1&2 and 3 between (D) 18 month WT and Tg 
mice and in (E) WT mice and (F) Tg mice aged 3, 9 and 18 months. Levels of 
APP were significantly increased in 18 month Tg mice compared to WT mice. 
PICALM band 3 expression was significantly decreased in 18 month Tg mice 
compared to WT mice and in 18 month Tg mice compared to 3 and 9 month Tg 
mice but was increased in 18 month WT mice compared to 3 and 9 month WT 
mice. Data are represented as mean ± S.E.M. *p< 0.05, one-way ANOVA 
followed by Tukey's post-hoc tests or unpaired Student’s t-tests. n=3-4 mice for 
each age group. 
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Figure 2. Comparison of Aβ40, Aβ42 and caveolin-1 in the cortex of male WT 
and Tg mice aged 3, 9 and 18 months. The caveolin-1 sections each show an 
immunoblot and densitometric analysis of the immunoblot. Comparison of 
soluble (A) and insoluble (B) Aβ40 and 42 in Tg mice aged 3, 9 and 18 months; 
comparison of caveolin-1 expression in (C) WT mice and (D) Tg mice aged 3, 9 
and 18 months; (E) comparison of caveolin-1 expression in 18 month WT and 
Tg mice; Soluble and insoluble Aβ40 was significantly increased in 18 month Tg 
mice compared to 3 and 9 month mice while soluble Aβ42 was significantly 
increased in 18 month Tg mice compared to 9 month mice. Levels of caveolin-1 
were significantly increased in 9 and 18 month WT and Tg mice compared to 
the corresponding 3 month mice. Caveolin-1 expression was significantly 
decreased in 18 month Tg mice compared to WT mice. Data are represented as 
mean ± S.E.M. *p< 0.05, **p<0.01, ELISAs Kruskal-Wallis followed by Dunn’s 
multiple comparisons test (soluble Aβ) or one-way ANOVA followed by Fisher’s 
LSD test (insoluble Aβ40); Western blots one-way ANOVA followed by Tukey's 
post-hoc tests or unpaired Student’s t-tests. n=3-4 mice for each age group. 
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Supplementary Figure 1 Comparison of the expression of several proteins in 
the cortex of male WT and Tg mice aged 3, 9 and 18 months. Each section 
shows an immunoblot and densitometric analysis of the immunoblot. 
Comparison of APP expression in (A) WT mice and (B) Tg mice; comparison of 
Dynamin-1 expression in (C) WT mice and (D) Tg mice; comparison of Bin-1 
expression in (E) WT mice and (F) Tg mice; comparison of Caveolin-2 
expression in (G) WT mice and (H) Tg mice; comparison of Flotillin-1 
expression in (I) WT mice and (J) Tg mice; comparison of Flotillin-2 expression 
in (K) WT mice and (L) Tg mice. There were no significant differences between 
any groups for all proteins. n=3 mice for each age group. 
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Supplemental Digital content 2 
 
Table showing the comparison of expression levels of endocytic proteins 
between WT and Tg London V717I mice 
 
Protein/Age WT mice1 Tg mice1 
 OD ratio relative to GAPDH 
Clathrin, 3 month 0.7 ± 0.1 0.7 ± 0.1 
Clathrin, 9 month 0.8 ± 0.1* 0.3 ± 0.1 
Clathrin, 18 month 1.3 ± 0.2 1.9 ± 0.5 
Dynamin 1, 3 month 1.1 ± 0.03 0.9 ± 0.1 
Dynamin 1, 9 month 1.1 ± 0.02 0.9 ± 0.1 
Dynamin 1, 18 month 1.1 ± 0.1 0.9 ± 0.1 
PICALM bands 1&2, 3 month 0.8 ± 0.1 0.8 ± 0.1 
PICALM band 3, 3 month 0.8 ± 0.1 0.7 ± 0.04 
PICALM bands 1&2, 9 month 0.8 ± 0.1 0.9 ± 0.1 
PICALM band 3, 9 month 0.8 ± 0.2 0.7 ± 0.1 
Bin-1, 3 month 0.8 ± 0.1 0.7 ± 0.2 
Bin-1, 9 month 2.3 ± 0.5 2.5 ± 0.5 
Bin-1, 18 month 1.1 ± 0.2 0.9 ± 0.2 
Caveolin-1, 3 month 1.1 ± 0.1 0.9 ± 0.3 
Caveolin-1, 9 month 1.0 ± 0.2 0.9 ± 0.1 
Caveolin-2, 3 month 0.9 ± 0.03 0.8 ± 0.1 
Caveolin-2, 9 month 0.9 ± 0.04 0.9 ± 0.1 
Caveolin-2, 18 month 1.0 ± 0.1 1.1 ± 0.1 
Flotillin-1, 3 month 1.2 ± 0.1 1.2 ± 0.1 
Flotillin-1, 9 month 1.6 ± 0.3 1.5 ± 0.1 
Flotillin-1, 18 month 0.9 ± 0.1 0.8 ± 0.1 
Flotillin-2, 3 month 1.0 ± 0.04 1.1 ± 0.2 
Flotillin-2, 9 month 1.1 ± 0.1 0.9 ± 0.1 
Flotillin-2, 18 month 0.9 ± 0.2 0.9 ± 0.1 
 
1
 * p,0.001, clathrin expression was significantly higher in 9 month WT mice 
compared to Tg mice analysed with an unpaired Student’s t-test. There were no 
other significant differences between WT and Tg mice for any of the proteins at 
the different ages. 
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